As Phase III evidence matures, route to market choices and launch sequencing become critical.
Preparing for success
As Phase III evidence matures, route to market choices and launch sequencing become critical. Drawing on our experience across Europe, Asia Pacific, Latin America and the Middle East, we identify optimal routes to access and shape launch pathways. We pride ourselves on delivering actionable recommendations derived from our comprehensive insights, ensuring a clear understanding and strategic direction to support your product success.
Our recommendations blend market insight with deep insight into payer psychology. Understanding payer needs, interests, and concerns is essential to truly shaping reimbursement outcomes.
Typical project types at this stage:
- Early access strategies
- Launch and sequencing strategies
- IRP risk assessment and mitigation
- Pricing and Access Strategies
- Payer, clinician and Key Opinion Leader research
- Stakeholder-tested pricing and access roadmaps
As Phase III evidence matures, route to market choices and launch sequencing become critical. Drawing on our experience across Europe, Asia Pacific, Latin America and the Middle East, we identify optimal routes to access and shape launch pathways. We pride ourselves on delivering actionable recommendations derived from our comprehensive insights, ensuring a clear understanding and strategic direction to support your product success.
Our recommendations blend market insight with deep insight into payer psychology. Understanding payer needs, interests, and concerns is essential to truly shaping reimbursement outcomes.
Typical project types at this stage:
- Early access strategies
- Launch and sequencing strategies
- IRP risk assessment and mitigation
- Pricing and Access Strategies
- Payer, clinician and Key Opinion Leader research
- Stakeholder-tested pricing and access roadmaps
Substantiating value
Communicating value is more than listing clinical endpoints and economic impact; it means translating trial data into concise, payer-relevant narratives that can withstand HTA scrutiny across markets.
At Valid Insight, our goal is to reveal your product’s true value, facilitating optimal pricing, reimbursement, and smooth market access. We create materials that are user-friendly, concise, and easily adaptable, ensuring consistent messaging that aligns with your brand strategy and market access goals. We believe effective value communication should be clear, engaging, and lively, avoiding the repetitive clutter that often plagues value materials. Our value tools are cantered around a payer-focused narrative, steering clear of generic statements and solely clinical messages.
Key project types include:
- Systematic/targeted literature reviews and evidence synthesis
- Economic model development
- Value proposition and narrative development
- Global value dossier development
- Value message testing with key stakeholders
- Consensus statements, including Delphi panels/ advisory boards
- A wide range of manuscript publications
Communicating value is more than listing clinical endpoints and economic impact; it means translating trial data into concise, payer-relevant narratives that can withstand HTA scrutiny across markets.
At Valid Insight, our goal is to reveal your product’s true value, facilitating optimal pricing, reimbursement, and smooth market access. We create materials that are user-friendly, concise, and easily adaptable, ensuring consistent messaging that aligns with your brand strategy and market access goals. We believe effective value communication should be clear, engaging, and lively, avoiding the repetitive clutter that often plagues value materials. Our value tools are cantered around a payer-focused narrative, steering clear of generic statements and solely clinical messages.
Key project types include:
- Systematic/targeted literature reviews and evidence synthesis
- Economic model development
- Value proposition and narrative development
- Global value dossier development
- Value message testing with key stakeholders
- Consensus statements, including Delphi panels/ advisory boards
- A wide range of manuscript publications
